Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

PROK

ProKidney Corp

Feb 13 • 04:00PM ET

1.98

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: FMS DVA OPK NEPH RMTI AKBA MNKD ARDX ADMA PDEX

| Held by: VXF SCHA BBC SCHB

Index	-	P/E	-	EPS (ttm)	-0.54	Insider Own	27.00%	Shs Outstand	135.98M	Perf Week	5.88%
Market Cap	280.25M	Forward P/E	-	EPS next Y	-0.62	Insider Trans	-0.92%	Shs Float	103.33M	Perf Month	-13.16%
Enterprise Value	1.34B	PEG	-	EPS next Q	-0.15	Inst Own	32.33%	Short Float	15.11%	Perf Quarter	-26.12%
Income	-71.03M	P/S	378.72	EPS this Y	7.21%	Inst Trans	3.35%	Short Ratio	13.16	Perf Half Y	-18.18%
Sales	0.74M	P/B	-	EPS next Y	-6.97%	ROA	-17.19%	Short Interest	15.61M	Perf YTD	-11.61%
Book/sh	-7.41	P/C	1.03	EPS next 5Y	8.37%	ROE	-	52W High	7.13 -72.23%	Perf Year	23.75%
Cash/sh	1.92	P/FCF	-	EPS past 3/5Y	11.32% -	ROIC	-	52W Low	0.46 330.15%	Perf 3Y	-83.66%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-654.57%	Volatility	8.65% 7.59%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1809.62	EPS Y/Y TTM	2.35%	Oper. Margin	-22296.10%	ATR (14)	0.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.32	Sales Y/Y TTM	-	Profit Margin	-9547.45%	RSI (14)	44.04	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.32	EPS Q/Q	14.08%	SMA20	-3.46%	Beta	1.81	Target Price	6.25
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-10.44%	Rel Volume	0.31	Prev Close	1.98
Employees	204	LT Debt/Eq	-	Earnings	Nov 10 AMC	SMA200	-9.01%	Avg Volume	1.19M	Price	1.98
IPO	Jun 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.71% 267.80%	Trades		Volume	364,964	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-16-25	Initiated	H.C. Wainwright	Buy	$12
Jun-30-25	Downgrade	BofA Securities	Neutral → Underperform	$1
Sep-30-24	Initiated	JP Morgan	Neutral
Sep-10-24	Initiated	Guggenheim	Buy	$6
Mar-07-24	Resumed	Morgan Stanley	Equal-Weight	$3
Jan-02-24	Downgrade	BofA Securities	Buy → Neutral
Jul-25-23	Initiated	BTIG Research	Buy	$16
Dec-21-22	Initiated	Jefferies	Buy	$15
Nov-10-22	Initiated	Morgan Stanley	Equal-Weight	$13
Oct-18-22	Initiated	UBS	Buy	$18
Oct-14-22	Initiated	Citigroup	Buy	$16
Sep-23-22	Initiated	BofA Securities	Buy	$14
Sep-02-22	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Jan-06-26 07:30AM	ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +5.14%
Dec-27-25 07:43AM	ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright (Insider Monkey)
Dec-16-25 11:53AM	Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy (PR Newswire) +5.77%
Nov-10-25 04:15PM	ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates (GlobeNewswire) -6.57%
Nov-06-25 11:00AM	ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 (GlobeNewswire)
07:30AM	Loading…
Oct-29-25 07:30AM	ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference (GlobeNewswire)
Oct-20-25 07:30AM	ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025 (GlobeNewswire) +10.77%
Sep-20-25 02:43AM	ProKidney Corp (PROK) Touts Reparencel Therapy for Growth (Insider Monkey)
Aug-27-25 07:30AM	ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-12-25 04:01PM	ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates (GlobeNewswire) +5.80%
Jul-22-25 11:03AM	ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement (Insider Monkey) -5.28%
04:52AM	Meet the Biotech Stock That Rocketed 775% Higher (Motley Fool)
Jul-20-25 12:35AM	JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK) (Insider Monkey)
Jul-17-25 12:00PM	PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) -5.63%
10:00AM	Best Momentum Stocks to Buy for July 17th (Zacks)
06:40AM	Loading…
06:40AM	This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy? (Motley Fool)
05:38AM	New Strong Buy Stocks for July 17th (Zacks)
Jul-16-25 12:00PM	ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy? (Zacks) +10.68%
Jul-15-25 07:30AM	ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel (GlobeNewswire) -8.67%
Jul-14-25 09:45AM	ProKidney Just Set a New 52-Week High. Should You Buy, Sell, or Hold PROK Stock Here? (Barchart) -18.72%
Jul-12-25 07:30AM	'Story' stocks are smoking hot in 2025. This is how it could end badly for investors. (MarketWatch)
Jul-09-25 12:26PM	PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study (Zacks) +16.35%
07:51AM	ProKidney, Meta & EssilorLuxottica, Apple COO: Trending Tickers (Yahoo Finance Video)
07:30AM	ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference (GlobeNewswire)
Jul-08-25 05:09PM	ProKidney's stock rockets on 'intriguing' news, but analyst doesn't recommend buying (MarketWatch) +515.00%
07:00AM	ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes (GlobeNewswire)
Jul-01-25 12:43PM	ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware (GlobeNewswire)
Jun-30-25 09:36AM	Circle initiated, Disney upgraded: Wall Street's top analyst calls (The Fly) -11.46%
May-12-25 04:15PM	ProKidney Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) +15.79%
Mar-21-25 09:55AM	Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK) (Zacks)
07:30AM	Loading…
Mar-17-25 07:30AM	ProKidney Reports Full Year 2024 Financial Results and Business Highlights (GlobeNewswire) +5.73%
Jan-07-25 07:30AM	ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-26-24 07:30AM	ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference (GlobeNewswire)
Nov-12-24 07:30AM	ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting (GlobeNewswire)
Nov-05-24 07:30AM	ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-22-24 07:02PM	Suvretta Capital Management's Strategic Acquisition in ProKidney Corp (GuruFocus.com) -8.11%
Oct-14-24 07:30AM	ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024 (GlobeNewswire)
Oct-09-24 07:30AM	ProKidney to Participate in the UBS Virtual Organ Restoration Day (GlobeNewswire)
Sep-04-24 01:33PM	ProKidney drops Phase III CKD study to focus on US market and save up to $175m (Clinical Trials Arena) -9.17%
Sep-03-24 07:30AM	ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S. (GlobeNewswire)
Aug-27-24 07:30AM	ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire) -7.53%
Aug-09-24 07:00AM	ProKidney Reports Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-27-24 05:52AM	PROK Stock Earnings: ProKidney Reported Results for Q4 2023 (InvestorPlace) +6.61%
Jun-26-24 02:10PM	Hedge Fund and Insider Trading News: Crispin Odey, Boaz Weinstein, Ken Griffin, Greenlight Capital, Eisler Capital, ProKidney Corp (PROK), Essex Property Trust Inc (ESS), and More (Insider Monkey)
Jun-17-24 07:00AM	ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters' Option (GlobeNewswire) +6.96%
Jun-11-24 09:35PM	ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering (GlobeNewswire) -19.87% +23.55%
07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-10-24 04:15PM	ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering (GlobeNewswire) -5.33%
07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:30AM	ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates (GlobeNewswire)
May-29-24 07:00AM	ProKidney to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) +6.74%
May-21-24 07:00AM	ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024 (GlobeNewswire)
May-10-24 03:43PM	ProKidney Corp Reports First Quarter 2024 Financial Results (GuruFocus.com) +7.66%
01:54PM	PROK Stock Earnings: ProKidney Beats EPS for Q1 2024 (InvestorPlace)
07:48AM	ProKidney Q1 Loss Unchanged From Year Earlier (MT Newswires)
07:00AM	ProKidney Reports Business Updates and First Quarter 2024 Financial Results (GlobeNewswire)
Mar-25-24 06:05AM	ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations (GlobeNewswire)
Mar-21-24 07:49PM	ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -6.16%
Feb-29-24 04:05PM	ProKidney to Participate in Jefferies Biotech on the Bay Summit (GlobeNewswire)
Dec-29-23 08:22AM	Chamath Palihapitiya Stocks: 12 Stocks Pumped in the Last 10 Years (Insider Monkey)
Dec-13-23 09:55AM	Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now (Zacks) +9.60%
Nov-30-23 06:05AM	ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer (GlobeNewswire) -10.16%
Nov-24-23 06:40AM	7 Penny Stocks With Low Floats and High Short Interest (InvestorPlace)
Nov-21-23 06:05AM	ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference (GlobeNewswire) +5.68%
Nov-17-23 01:38PM	ProKidney Corp. (NASDAQ:PROK) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-16-23 09:35AM	After Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK) (Zacks) -11.51%
Nov-14-23 07:04AM	ProKidney Corp (PROK) Reports Q3 Financial Results: Focus on Chronic Kidney Disease Trials (GuruFocus.com) -5.00%
06:05AM	ProKidney Reports Third Quarter Financial Results (GlobeNewswire)
Nov-13-23 05:02PM	ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT ) for Diabetic CKD and Provides Corporate Updates (GlobeNewswire)
Oct-30-23 04:12PM	ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2023 (GlobeNewswire) +12.29%
Oct-17-23 09:35AM	ProKidney Corp. (PROK) Loses -54.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -7.93%
Oct-16-23 02:50PM	Is Chamath Palihapitiya Giving Up on ProKidney (PROK) Stock? (InvestorPlace)
Oct-12-23 03:05PM	Why Shares of ProKidney Were Dropping Thursday (Motley Fool) -31.45%
Sep-06-23 12:14PM	ProKidney confirms it will expand HQ complex, add 50 jobs in Winston-Salem (American City Business Journals)
Sep-05-23 06:05AM	ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-31-23 10:33AM	3 Biotech Stocks Due for a Massive Short Squeeze (InvestorPlace)
Aug-29-23 01:16PM	ProKidney confirmed as company seeking incentives to expand in Forsyth County (American City Business Journals)
Aug-11-23 02:21PM	ProKidney reports $38.8 million loss in Q2 FY2023 as it advances clinical trials and prepares for Greensboro manufacturing expansion (American City Business Journals)
Aug-10-23 04:10PM	ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights (GlobeNewswire)
Jul-18-23 06:05AM	ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC (GlobeNewswire)
Jul-17-23 06:05AM	ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization (GlobeNewswire) +6.65%
Jun-13-23 12:05PM	ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC (GlobeNewswire)
Jun-01-23 04:05PM	ProKidney to Participate in Fireside Chat at the Jefferies Healthcare Conference (GlobeNewswire) -7.66%
May-11-23 04:01PM	ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-04-23 06:05AM	ProKidney to Present at the BofA Securities Health Care Conference 2023 (GlobeNewswire)
Apr-25-23 02:00PM	We're Interested To See How ProKidney (NASDAQ:PROK) Uses Its Cash Hoard To Grow (Simply Wall St.) -8.73%
Mar-28-23 04:12PM	ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights (GlobeNewswire) -7.39%
Mar-03-23 06:05AM	ProKidney to Participate in TD Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Jan-11-23 07:48AM	ProKidneys stock jumps 29% (MarketWatch)
Jan-10-23 04:05PM	ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease (GlobeNewswire) +9.57%
Dec-27-22 11:05AM	Chamath Palihapitiya Stocks: 10 Stocks Picked in the Last 10 Years (Insider Monkey) -5.82%
08:46AM	A Look At The Intrinsic Value Of ProKidney Corp. (NASDAQ:PROK) (Simply Wall St.)
Dec-22-22 06:05AM	ProKidney to Present at the J.P. Morgan 41st Annual Healthcare Conference (GlobeNewswire)
Nov-16-22 11:22AM	ProKidney (NASDAQ:PROK) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Nov-14-22 06:05AM	ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-11-22 04:05PM	ProKidney to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.85%
Nov-03-22 06:05AM	ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease (GlobeNewswire)
Oct-14-22 12:00PM	ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrologys Kidney Week 2022 (GlobeNewswire)
Sep-23-22 06:15AM	ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit (GlobeNewswire)
Sep-08-22 06:05AM	ProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pereira Brian JG	Director	Nov 13 '25	Sale	2.37	502,136	1,190,062	0	Nov 14 04:07 PM
Pereira Brian JG	Director	Nov 12 '25	Sale	2.72	255,026	694,515	54,333	Nov 14 04:07 PM
Brian Pereira	Director	Nov 12 '25	Proposed Sale	2.70	675,234	1,823,131		Nov 12 04:42 PM
Brian Pereira	Director	Nov 12 '25	Proposed Sale	2.70	81,928	221,205		Nov 12 04:30 PM
Weber Darin J.	Chief Regulatory Officer	Jul 08 '25	Sale	3.02	103,480	312,510	0	Jul 09 04:28 PM
DARIN J WEBER	Officer	Jul 08 '25	Proposed Sale	0.61	103,480	62,761		Jul 08 04:20 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Apr 22 '25	Buy	0.71	387,393	276,366	73,842,723	Apr 24 04:15 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Apr 17 '25	Buy	0.75	25,000	18,690	73,455,330	Apr 21 04:37 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Apr 16 '25	Buy	0.75	100,000	74,820	73,430,330	Apr 18 04:15 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Apr 15 '25	Buy	0.70	468,000	326,009	73,330,330	Apr 16 05:04 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Apr 14 '25	Buy	0.73	268,105	194,591	72,862,330	Apr 16 05:04 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Apr 10 '25	Buy	0.61	1,032,218	627,692	72,592,325	Apr 14 04:30 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Apr 11 '25	Buy	0.61	1,900	1,155	72,594,225	Apr 14 04:30 PM

Open in Screener

RPRX

Royalty Pharma plc

Feb 13 • 04:00PM ET

45.19

+0.39 0.87 %

Healthcare • Biotechnology • USA • NASD

RPRX Royalty Pharma plc daily Stock Chart

Peers: BIIB REGN VRTX GILD INCY ALNY EXEL NBIX MDGL DKNG

| Held by: VFLO VXF IWR VYM SCHM IHE IWD COWG DGRO IWS

Index	-	P/E	25.38	EPS (ttm)	1.78	Insider Own	8.98%	Shs Outstand	428.67M	Perf Week	1.21%
Market Cap	19.31B	Forward P/E	8.62	EPS next Y	5.24	Insider Trans	-2.37%	Shs Float	389.93M	Perf Month	12.38%
Enterprise Value	30.87B	PEG	1.16	EPS next Q	1.07	Inst Own	84.75%	Short Float	6.79%	Perf Quarter	14.14%
Income	770.74M	P/S	8.12	EPS this Y	0.71%	Inst Trans	3.04%	Short Ratio	6.58	Perf Half Y	23.81%
Sales	2.38B	P/B	2.99	EPS next Y	7.79%	ROA	4.07%	Short Interest	26.46M	Perf YTD	16.95%
Book/sh	15.11	P/C	30.29	EPS next 5Y	7.40%	ROE	11.48%	52W High	45.27 -0.18%	Perf Year	39.22%
Cash/sh	1.49	P/FCF	7.44	EPS past 3/5Y	163.11% -7.26%	ROIC	5.12%	52W Low	29.66 52.36%	Perf 3Y	18.92%
Dividend Est.	0.98 (2.16%)	EV/EBITDA	19.77	Sales past 3/5Y	2.06% 2.30%	Gross Margin	-	Volatility	3.09% 2.04%	Perf 5Y	-5.81%
Dividend TTM	0.88 (1.95%)	EV/Sales	12.98	EPS Y/Y TTM	-7.01%	Oper. Margin	65.56%	ATR (14)	0.94	Perf 10Y	-
Dividend Ex-Date	Feb 20, 2026	Quick Ratio	2.40	Sales Y/Y TTM	5.05%	Profit Margin	32.41%	RSI (14)	77.54	Recom	1.42
Dividend Gr. 3/5Y	5.01% 24.01%	Current Ratio	2.40	EPS Q/Q	6.83%	SMA20	7.18%	Beta	0.40	Target Price	51.71
Payout	49.40%	Debt/Eq	1.38	Sales Q/Q	4.71%	SMA50	11.79%	Rel Volume	1.34	Prev Close	44.80
Employees	100	LT Debt/Eq	1.33	Earnings	Feb 11 BMO	SMA200	21.83%	Avg Volume	4.02M	Price	45.19
IPO	Jun 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.02% 8.31%	Trades		Volume	5,403,705	Change	0.87%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-26	Upgrade	UBS	Neutral → Buy	$49
Sep-30-25	Initiated	Goldman	Buy	$42
May-16-25	Initiated	Morgan Stanley	Overweight	$51
Jun-03-24	Downgrade	UBS	Buy → Neutral	$28
Jun-14-22	Resumed	UBS	Buy	$47
May-13-22	Initiated	Scotiabank	Sector Outperform	$53
Apr-27-22	Initiated	Goldman	Buy	$56
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight	$50
Apr-06-22	Resumed	Morgan Stanley	Overweight	$48
Oct-29-21	Upgrade	Citigroup	Neutral → Buy	$50
Jul-30-21	Initiated	Tigress Financial	Buy	$50
Nov-09-20	Upgrade	UBS	Neutral → Buy	$52 → $51
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	UBS	Neutral	$52
Jul-13-20	Initiated	SunTrust	Buy	$56
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight	$51
Jul-13-20	Initiated	JP Morgan	Neutral	$50
Jul-13-20	Initiated	Goldman	Neutral	$47
Jul-13-20	Initiated	Cowen	Outperform	$55
Jul-13-20	Initiated	Citigroup	Neutral	$50

Show Previous Ratings

Feb-12-26 09:07PM	Vertex Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
Feb-11-26 02:02PM	Royalty Pharma PLC (RPRX) Q4 2025 Earnings Call Highlights: Strong Growth and Strategic Capital ... (GuruFocus.com)
12:32PM	Royalty Pharma plc Q4 2025 Earnings Call Summary (Moby)
09:52AM	Royalty Pharma Q4 Earnings Call Highlights (MarketBeat)
09:30AM	Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings (Zacks)
07:32AM	Loading…
07:32AM	Royalty Pharma: Q4 Earnings Snapshot (Associated Press Finance)
07:25AM	Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings (StockStory)
07:00AM	Royalty Pharma Reports Q4 and Full Year 2025 Results (GlobeNewswire)
Feb-10-26 09:15AM	Exploring Analyst Estimates for Royalty Pharma (RPRX) Q4 Earnings, Beyond Revenue and EPS (Zacks)
06:41AM	UBS and Citi Are Bullish on Royalty Pharma Plc (RPRX) - Here's Why (Insider Monkey)
Feb-09-26 10:06PM	What To Expect From Royalty Pharma's (RPRX) Q4 Earnings (StockStory)
Feb-05-26 11:38PM	3 Mid-Cap Stocks We Keep Off Our Radar (StockStory)
10:00AM	Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-04-26 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-24-26 06:37AM	Jim Cramer on Royalty Pharma: "It's a Terrific Company" (Insider Monkey)
05:42AM	Loading…
Jan-23-26 05:42AM	Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last? (Zacks)
Jan-22-26 08:53PM	Lightning Round: Coherent is a winner, says Jim Cramer (CNBC TV)
Jan-20-26 04:15PM	Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 (GlobeNewswire)
Jan-12-26 12:26PM	Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug (Benzinga)
10:08AM	TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug (Zacks)
08:55AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
07:15AM	Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-11-26 05:15PM	Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo (GlobeNewswire)
Jan-09-26 08:55AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
08:30AM	Royalty Pharma Announces Dividend Increase (GlobeNewswire)
01:52AM	Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal - Stock Soars Overnight (Benzinga)
Jan-07-26 10:37PM	Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX) (StockStory)
Dec-29-25 04:40PM	Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones (GlobeNewswire)
Dec-16-25 07:15AM	Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million (GlobeNewswire)
Dec-12-25 10:47AM	Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance (PR Newswire)
09:56AM	Loading…
Dec-05-25 09:56AM	Denali Enters Into a $275M Funding Deal With Royalty Pharma (Zacks)
07:05AM	Denali makes $275m funding agreement with Royalty Pharma (Pharmaceutical Business Review)
Dec-04-25 07:10AM	Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement (GlobeNewswire)
Nov-26-25 08:15AM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-24-25 06:12AM	Vaximm and BCME link on oral cancer immunotherapy platform (Pharmaceutical Technology)
Nov-14-25 12:56PM	Eli Lilly Leads Three Stocks Near Buy Points (Investor's Business Daily)
Nov-12-25 11:03PM	Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Nov-05-25 04:49PM	Analyst Report: Royalty Pharma plc (Morningstar Research) +6.82%
02:03PM	Royalty Pharma PLC (RPRX) Q3 2025 Earnings Call Highlights: Strong Portfolio Growth and ... (GuruFocus.com)
09:30AM	Royalty Pharma (RPRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:25AM	Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:23AM	Royalty Pharma: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Royalty Pharma Reports Third Quarter 2025 Results (GlobeNewswire)
Nov-04-25 07:15AM	Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences (GlobeNewswire)
Nov-03-25 10:34PM	Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2 (StockStory)
10:15PM	What To Expect From Royalty Pharma's (RPRX) Q3 Earnings (StockStory)
Oct-31-25 12:41PM	How Royalty Pharma Prints Cash Without Biotech's Biggest Risks (MarketBeat)
Oct-29-25 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
12:02AM	2 Reasons to Avoid RPRX and 1 Stock to Buy Instead (StockStory)
Oct-28-25 01:34PM	1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data (MarketBeat)
12:24PM	What Do Analysts Think About Royalty Pharma Plc (RPRX)? (Insider Monkey)
Oct-17-25 09:10AM	Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains? (Zacks)
08:15AM	Royalty Pharma Declares Fourth Quarter 2025 Dividend (GlobeNewswire)
Oct-14-25 07:45AM	Kailera nets $600M more to advance Zepbound-like obesity drug (BioPharma Dive)
Oct-09-25 04:15PM	Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-08-25 12:10PM	Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-06-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Oct-03-25 08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Sep-29-25 08:15AM	Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director (GlobeNewswire)
Sep-23-25 07:10PM	Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth (Insider Monkey)
Sep-19-25 04:25PM	Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum (GlobeNewswire)
Sep-17-25 02:27PM	TD Cowen Maintains a Buy on Royalty Pharma (RPRX) (Insider Monkey)
12:43AM	1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore (StockStory)
Sep-16-25 09:28AM	Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts (Insider Monkey)
Sep-11-25 11:13AM	Royalty Pharma plc (RPRX) Commits $300M to Zenas' Obexelimab Program (Insider Monkey)
07:00AM	Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation (GlobeNewswire)
Sep-10-25 07:30AM	Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market (GlobeNewswire)
Sep-04-25 04:15PM	Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Sep-02-25 08:30PM	Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes (GlobeNewswire)
07:15AM	Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million (GlobeNewswire)
Aug-29-25 02:57PM	Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase (Insider Monkey)
05:05AM	Royalty Pharma plc (RPRX) Boosts Growth with $885M Amgen Imdelltra Royalty Deal (Insider Monkey)
04:54AM	Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines (Insider Monkey)
Aug-25-25 01:19PM	BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up (Benzinga)
08:29AM	Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales (BioPharma Dive)
06:33AM	Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug (Reuters)
06:10AM	Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million (GlobeNewswire)
06:00AM	BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million (Business Wire)
Aug-13-25 04:15PM	Henry Fernandez Steps Down from Royalty Pharma's Board of Directors (GlobeNewswire)
01:35AM	5 Insightful Analyst Questions From Royalty Pharma's Q2 Earnings Call (StockStory)
Aug-12-25 09:10AM	Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT (Insider Monkey)
03:18AM	RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments (StockStory)
Aug-10-25 11:31PM	Reflecting On Branded Pharmaceuticals Stocks' Q2 Earnings: Royalty Pharma (NASDAQ:RPRX) (StockStory)
Aug-06-25 05:45PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
04:02PM	Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
09:30AM	Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings (Zacks)
08:20AM	Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates (Zacks)
08:08AM	Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue Estimates (StockStory)
07:22AM	Royalty Pharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Royalty Pharma Reports Second Quarter 2025 Results (GlobeNewswire)
Aug-05-25 09:15AM	Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Aug-04-25 11:21PM	Earnings To Watch: Royalty Pharma (RPRX) Reports Q2 Results Tomorrow (StockStory)
Jul-30-25 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
12:02AM	2 Reasons to Watch RPRX and 1 to Stay Cautious (StockStory)
Jul-18-25 08:15AM	Royalty Pharma Declares Third Quarter 2025 Dividend (GlobeNewswire)
Jul-17-25 08:15AM	Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors (GlobeNewswire)
Jul-16-25 04:15PM	Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-01-25 06:20AM	Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)? (Zacks)
Jun-27-25 08:33AM	5 Revealing Analyst Questions From Royalty Pharma's Q1 Earnings Call (StockStory)
Jun-24-25 07:05AM	Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion (GlobeNewswire)

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coyne Terrance P.	EVP & CFO	Feb 03 '26	Sale	42.84	114,954	4,924,997	23,972	Feb 04 05:07 PM
Coyne Terrance P.	EVP & CFO	Feb 02 '26	Sale	42.08	108,424	4,562,905	30,167	Feb 04 05:07 PM
Coyne Terrance P.	EVP & CFO	Feb 04 '26	Sale	43.29	20,163	872,913	22,885	Feb 04 05:07 PM
Terrance Coyne	Officer	Feb 03 '26	Proposed Sale	42.97	135,117	5,805,977		Feb 03 05:31 PM
Terrance Coyne	Officer	Feb 02 '26	Proposed Sale	42.36	108,424	4,592,841		Feb 02 05:28 PM
Urist Marshall	EVP, Research & Investments	Jan 30 '26	Sale	41.09	20,000	821,810	0	Feb 02 04:59 PM
Urist Marshall	EVP, Research & Investments	Jan 23 '26	Sale	40.26	20,000	805,110	20,000	Jan 26 04:10 PM
Coyne Terrance P.	EVP & CFO	Jan 20 '26	Sale	39.35	69,582	2,737,940	36,010	Jan 23 04:48 PM
Urist Marshall	EVP, Research & Investments	Jan 16 '26	Sale	39.52	20,000	790,346	40,000	Jan 20 05:00 PM
Terrance Coyne	Officer	Jan 20 '26	Proposed Sale	39.09	69,582	2,719,960		Jan 20 04:55 PM
Urist Marshall	EVP, Research & Investments	Jan 09 '26	Sale	40.78	20,000	815,634	60,000	Jan 13 05:37 PM
George Lloyd	Officer	Jan 07 '26	Proposed Sale	41.39	495,860	20,523,645		Jan 07 05:03 PM
Coyne Terrance P.	EVP & CFO	Jan 02 '26	Sale	38.42	69,582	2,673,041	39,760	Jan 06 04:18 PM
Urist Marshall	EVP, Research & Investments	Jan 02 '26	Sale	38.48	20,000	769,650	80,000	Jan 06 04:17 PM
Terrance Coyne	Officer	Jan 02 '26	Proposed Sale	38.86	69,582	2,703,957		Jan 02 06:22 PM
Urist Marshall	EVP, Research & Investments	Dec 26 '25	Sale	39.32	20,000	786,380	100,000	Dec 29 04:58 PM
Urist Marshall	EVP, Research & Investments	Dec 19 '25	Sale	38.38	20,000	767,582	120,000	Dec 22 04:09 PM
Lloyd George W.	EVP, Investments & CLO	Dec 17 '25	Sale	38.57	79,346	3,060,280	30,654	Dec 19 05:24 PM
Lloyd George W.	EVP, Investments & CLO	Dec 18 '25	Sale	38.50	30,654	1,180,053	0	Dec 19 05:24 PM
Urist Marshall	EVP, Research & Investments	Dec 16 '25	Sale	38.32	20,000	766,420	140,000	Dec 17 05:43 PM
Coyne Terrance P.	EVP & CFO	Dec 15 '25	Sale	38.36	69,582	2,669,172	43,510	Dec 17 05:39 PM
Sandy Lamm LLC	Officer	Dec 16 '25	Proposed Sale	38.36	160,000	6,137,600		Dec 16 09:41 PM
Terrance Coyne	Officer	Dec 15 '25	Proposed Sale	38.53	69,582	2,680,994		Dec 15 06:22 PM
Urist Marshall	EVP, Research & Investments	Dec 05 '25	Sale	39.15	23,334	913,591	160,000	Dec 09 05:00 PM
Urist Marshall	EVP, Research & Investments	Dec 05 '25	Sale	39.15	18,242	714,224	7,398	Dec 09 05:00 PM
Lloyd George W.	EVP, Investments & CLO	Dec 03 '25	Sale	39.77	110,000	4,375,008	110,000	Dec 05 05:01 PM
Coyne Terrance P.	EVP & CFO	Dec 01 '25	Sale	39.87	69,582	2,773,956	47,260	Dec 03 05:11 PM
Urist Marshall	EVP, Research & Investments	Dec 01 '25	Sale	39.93	23,333	931,633	183,334	Dec 03 05:10 PM
Urist Marshall	EVP, Research & Investments	Dec 01 '25	Sale	39.90	18,242	727,856	25,640	Dec 03 05:10 PM
Terrance Coyne	Officer	Dec 01 '25	Proposed Sale	39.90	69,582	2,776,322		Dec 01 05:53 PM
Urist Marshall	Officer	Dec 01 '25	Proposed Sale	39.90	36,484	1,455,712		Dec 01 05:10 PM
Sandy Lamm LLC	Officer	Dec 01 '25	Proposed Sale	19.93	46,667	930,232		Dec 01 04:48 PM
Coyne Terrance P.	EVP & CFO	Nov 24 '25	Sale	38.55	69,582	2,682,505	51,010	Nov 26 05:01 PM
Terrance Coyne	Officer	Nov 24 '25	Proposed Sale	39.75	69,582	2,765,884		Nov 24 05:24 PM
Lloyd George W.	EVP, Investments & CLO	Nov 19 '25	Sale	38.34	132,426	5,077,627	0	Nov 21 04:55 PM
Lloyd George W.	EVP, Investments & CLO	Nov 19 '25	Sale	38.34	3,000	115,029	0	Nov 21 04:55 PM
George Lloyd	Officer	Nov 19 '25	Proposed Sale	38.65	355,426	13,737,215		Nov 19 05:41 PM
Coyne Terrance P.	EVP & CFO	Nov 17 '25	Sale	39.30	69,594	2,735,329	54,760	Nov 19 04:53 PM
Terrance Coyne	Officer	Nov 17 '25	Proposed Sale	39.16	69,594	2,725,301		Nov 17 05:38 PM
Norden Gregory	Director	Aug 11 '25	Sale	36.23	33,500	1,213,749	194,848	Aug 11 04:35 PM
Norden Gregory	Director	Aug 11 '25	Proposed Sale	36.23	33,500	1,213,747		Aug 11 04:18 PM

PROK

ProKidney Corp

RPRX

Royalty Pharma plc

Upgrade your FINVIZ experience